HIV-1 gp41 MPER-656 Liposome Vaccine

· National Institute of Allergy and Infectious Diseases (NIAID)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HIV-1 gp41 MPER-656 Liposome Vaccine, covering 2022-05-12 to 2022-05-12. Get the full timeline:

Most recent: Clinical Trial Update: Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants [Phase 1]

See pricing